Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector, retaining the price target of $10.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Fein has given his Buy rating due to a combination of factors that highlight Alector’s diversified pipeline and potential for significant shareholder value. The company is advancing its pivotal INFRONT-3 trial for latozinemab in FTD-GRN, with multiple scenarios that could lead to stock price increases, depending on the trial outcomes. Even in the event of a setback in the FTD program, Alector’s new ABC platform candidates, including anti-Aβ antibodies for Alzheimer’s and a GCase enzyme replacement therapy for Parkinson’s, provide alternative avenues for growth and partnerships.
Furthermore, the potential of nivisnebart (AL101) in Alzheimer’s disease represents a crucial milestone for Alector. The ongoing Phase 2 trial is assessing its efficacy in early Alzheimer’s patients, with an independent interim analysis expected in the first half of 2026. Success in this area, along with promising biomarker data, could further bolster Alector’s standing in the neurodegenerative disease space, reinforcing Fein’s optimistic outlook on the company’s future prospects.
Fein covers the Healthcare sector, focusing on stocks such as Biogen, Palvella Therapeutics, and Savara. According to TipRanks, Fein has an average return of 16.6% and a 51.22% success rate on recommended stocks.